Ilias V Karagounis
Overview
Explore the profile of Ilias V Karagounis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
346
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koukourakis M, Giatromanolaki A, Zois C, Kalamida D, Pouliliou S, Karagounis I, et al.
Sci Rep
. 2025 Feb;
15(1):4069.
PMID: 39900942
No abstract available.
2.
Verginadis I, Avgousti H, Monslow J, Skoufos G, Chinga F, Kim K, et al.
Nat Cell Biol
. 2022 Jun;
24(6):940-953.
PMID: 35654839
Bidirectional signalling between the tumour and stroma shapes tumour aggressiveness and metastasis. ATF4 is a major effector of the Integrated Stress Response, a homeostatic mechanism that couples cell growth and...
3.
Van Slyke A, Khatib M, Velalopoulou A, Diffenderfer E, Shoniyozov K, Kim M, et al.
Radiat Res
. 2022 May;
198(2):181-189.
PMID: 35640166
FLASH is a high-dose-rate form of radiation therapy that has the reported ability, compared with conventional dose rates, to spare normal tissues while being equipotent in tumor control, thereby increasing...
4.
Velalopoulou A, Karagounis I, Cramer G, Kim M, Skoufos G, Goia D, et al.
Cancer Res
. 2021 Jul;
81(18):4808-4821.
PMID: 34321243
In studies of electron and proton radiotherapy, ultrahigh dose rates of FLASH radiotherapy appear to produce fewer toxicities than standard dose rates while maintaining local tumor control. FLASH-proton radiotherapy (F-PRT)...
5.
Thomas C, Karagounis I, Srivastava R, Vrettos N, Nikolos F, Francois N, et al.
Cancer Res
. 2021 Jan;
81(9):2399-2414.
PMID: 33514514
Inflammatory breast cancer (IBC) is a highly metastatic breast carcinoma with high frequency of estrogen receptor α (ERα) negativity. Here we explored the role of the second ER subtype, ERβ,...
6.
Carabe A, Karagounis I, Huynh K, Bertolet A, Francois N, Kim M, et al.
Phys Med Biol
. 2020 May;
65(16):165002.
PMID: 32413889
This paper aims to demonstrate the difference in biological effectiveness of proton monoenergetic arc therapy (PMAT) compared to intensity modulated proton therapy (IMPT) and conventional 6 MV photon therapy, and...
7.
Chao H, Karagounis I, Thomas C, Francois N, Facciabene A, Koumenis C, et al.
Oncogene
. 2020 Apr;
39(22):4344-4357.
PMID: 32335582
We explore a novel strategy of activating immune signaling through increased micronuclei formation utilizing a cell cycle checkpoint inhibitor to drive cell cycle progression following ionizing radiation. The Chk1/2 inhibitor...
8.
Lekoudi E, Kontargiris E, Karagounis I, Simos Y, Deligiannis I, Vadalouka A, et al.
Eur J Dermatol
. 2018 Jun;
28(3):409-410.
PMID: 29952289
No abstract available.
9.
Koukourakis M, Giatromanolaki A, Fylaktakidou K, Sivridis E, Zois C, Kalamida D, et al.
Invest New Drugs
. 2018 Feb;
36(5):773-781.
PMID: 29387992
Effective cytoprotectors that are selective for normal tissues could decrease radiotherapy and chemotherapy sequelae and facilitate the safe administration of higher radiation doses. This could improve the cure rates of...
10.
Koukourakis M, Giatromanolaki A, Fylaktakidou K, Kouroupi M, Sivridis E, Zois C, et al.
Anticancer Res
. 2017 Dec;
38(1):227-238.
PMID: 29277777
Background/aim: Amifostine is the only selective normal tissue cytoprotector, approved for the protection against platinum toxicities and radiotherapy-induced xerostomia. Free radical scavenger and DNA repair activities have been attributed to...